Fred Alger Management’s Cardlytics CDLX Stock Holding History

Fred Alger Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,582	Closed	-$13.4M	–	522
2021 Q2	$13.4M	Buy	+10,582	New	+$11.9M	0.03%	236

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fred Alger Management's CDLX Position: Q3 2021 in Review

Fred Alger Management sold out of Cardlytics (CDLX) in Q3 2021, closing a stake of 10,582 shares — an estimated $13.4M sold.

Fred Alger Management first reported a position in CDLX in Q2 2021 and held it in 1 quarter. The position peaked at $13.4M in Q2 2021. 164 funds tracked by Wall St. Rank hold CDLX as of Q3 2021.

Fred Alger Management reported no remaining Cardlytics position as of Q3 2021 after selling out during the quarter.
Fred Alger Management sold 10,582 Cardlytics shares in Q3 2021, an estimated $13.4M.
Fred Alger Management first reported a position in Cardlytics in Q2 2021 and held it in 1 quarter.
Fred Alger Management's Cardlytics position peaked at $13.4M in Q2 2021.
164 funds tracked by Wall St. Rank held Cardlytics as of Q3 2021.

Based on Fred Alger Management's 13F filing for Q3 2021, filed 15 Nov 2021.